Sepracor-Looks very promising Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (7321)	1/23/2004 9:39:21 AM
From: Biomaven	Read Replies (1) of 10280

>>By my quick count sepr has spent $1.1B in r&d since 1998 with no drug approvals.>> Not too different than the industry estimate of $800m per drug if you assume that Estorra and the MDI get approved. Despite the hiccups they have had, I don't see any other company in this MC range with near as promising a pipeline. If the cfc MDIs get taken off the market, then this stock is cheap based on Xopenex alone. BTW, on S-oxy they said something like the program was still a "valuable asset." My guess is that they are looking at the sustained release characteristics - maybe they need tweaking some. Competition in this area is going to heat up - may not be enough to just beat Detrol any more. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next